Therapeutic Hypobaric Normoxia for Hypertension


Description

Researchers at the University of Alberta are developing a non-invasive therapy to alter systemic vascular resistance by using hypobaric normoxia/hyperoxia as an adjuvant to standard medical therapy. Preliminary results studies in mouse models have shown that the therapy enhances arterial vasodilation, increases cardiac output, and lowers effective systemic vascular resistance without changing systemic mean arterial blood pressure. This technology has potential to be applied in treatment and management of many acute and chronic forms of cardiovascular disease, such as myocardial infarction, heart failure, peripheral artery disease and stroke.
Cardiovascular diseases are the leading cause of death worldwide. In the year 2005, approximately 17.5 million people (30% of global deaths) died from cardiovascular disease. The incidence and prevalence of cardiovascular diseases is increasing and it is expected that 20 million people will die from cardiovascular disease (mainly from heart attacks and strokes) by end of 2015. Availability of novel and effective non-invasive strategies will improve the current standard of living for people with cardiovascular ailments.

Advantages

 Non-invasive method to lower systemic vascular resistance and increase cardiac output
 Normoxia/hyperoxia conditions

Protection Status

Patents Pending

Product Number

2015016

Contact Information

Megha Bajaj
Technology Management Group
TEC Edmonton – University of Alberta
Phone: 780-492-7739
​Email: megha.bajaj@tecedmonton.com